Because CD22 and other B-cell markers are usually still expressed on CD19-negative tumor cells9,35, combinational targeting of CD19 and other tumor-associated antigens might be a feasible and superior solution than single-targeting of CD19 in TP53-disrupted B-cell lymphoma, although validation and investigation of underlying mechanism, including with or without ASCT, in prospective randomized control trials is warranted. The gene discussed is CD22; the disease is B-cell non-Hodgkin lymphoma.